Evidence map›Paper›PMID 36917399›Full record

ReviewOncology and therapy2023

Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review.

Paulo Nunes Filho, Caroline Albuquerque, Mariana Pilon Capella, Marcio Debiasi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 4 countries.

Paulo Nunes FilhoLabcorp Drug Development, Burlington, NC, USA. paulo.nunes@labcorp.com.ORCID http://orcid.org/0000-0002-4314-9230
Caroline AlbuquerqueHospital São Lucas da PUCRS, Porto Alegre, Brazil.
Mariana Pilon CapellaMcGill University, Montreal, Canada.
Marcio DebiasiBreast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
Champalimaud Foundation · PTHospital São Lucas da PUCRS · BRLabCorp (United States) · USMcGill University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most frequently diagnosed malignancy in patients worldwide and the main cause of cancer-related death. Though still incurable, metastatic breast cancer's prognosis has been considerably improved in the past 10 years due to the introduction of new targeted agents, such as immune checkpoint inhibitors (ICI). However, these medications are associated with unique side effects known as immune-mediated adverse events (irAE). In this paper, we review the clinical evidence for the use of ICIs in breast cancer, in both the metastatic as well as neoadjuvant/adjuvant setting, followed by a review of irAE most commonly seen, and the medications used to treat them. Our opinion is that any cancer specialist treating patients with breast cancer should be aware of these side effects for early detection and management, and oncologists should be the leaders of the multidisciplinary team that will take care of them.

Indexed as

Breast neoplasmsDrug-related side effects and adverse reactionsImmune checkpoint inhibitorsOncologistsPatient care team

Identifiers

PMID36917399
PMCPMC10260715
OpenAlexW4324129452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.